ArticleFrontiers in oncology2026

Retraction: PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults.

Frontiers Editorial OfficePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.